About Intradigm Corporation
Intradigm Corporation is a Healthcare company based in Palo Alto (United States) founded in 2000, and was acquired by Silence Therapeutics in December 2009. It develops RNA interference (RNAi) therapeutics for the treatment of cancer. It operates in the Healthcare and Technology sectors. Intradigm Corporation has raised $37.4 million across 2 funding rounds from investors including Roche, Novartis and Silence Therapeutics. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include Denali Therapeutics, C4 Therapeutics and Erasca; 3 of its 3 listed competitors have raised funding.
Company details
Intradigm Corporation was founded in 2000 and is based in Palo Alto, United States. Focus is placed on the biotechnology sector, where RNA interference therapeutics are developed for serious diseases, starting with oncology. Operations involve the use of proprietary Nanoplex delivery technology, which allows targeted administration to specific tissues via systemic drug delivery methods.
- Headquarters Palo Alto, United States
- Stage Acquired
- SectorsHealthcareTechnology
- Website intradigm.com
- Social LinkedIn
- Acquired by Silence Therapeutics (Dec 2009)
- Legal Name Intradigm Corporation
- Total Equity Funding$37.4M (USD)
in 2 rounds
- Latest Funding Round$21.4M (USD), Series B
Jan 2009
- InvestorsRoche
& 10 more
- Acquired bySilence Therapeutics
(Dec 2009)
Funding Insights of Intradigm Corporation
Intradigm Corporation has successfully raised a total of $37.4M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $21.4 million completed in January 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $37.4M
- Total Rounds 2
- Last Round Series B β $21.4M
- First Round $16M
(May 2006)
- Investors Count 10
All 2 funding rounds of Intradigm Corporation with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2009 | $21.4M | Series B | β | Astellas Venture Management | |
| May 2006 | $16M | Series A | β | β |
11 investors in total: 11 institutional.
Investors in Intradigm Corporation
Intradigm Corporation has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include Roche, Novartis and Silence Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A venture capital firm focused on life science innovations. | mp-healthcare.com | Cambridge, United States | ||
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
| astellasventure.com | ||||
Venture capital firm focused on healthcare companies | altapartners.com | Jackson, United States | ||
Early-stage life sciences investments are targeted in the healthcare sector. | lillyventures.com | Indianapolis, United States | ||
Genetic testing and analysis services are provided by MediBIC Group. | 2000 | medibic.com | Chiba, Japan | |
R&D focused on manufacturing of drugs for multiple therapeutic areas | 1996 | novartis.com | Basel, Switzerland | |
Pharmaceuticals and diagnostics kits are developed for various diseases. | 1896 | roche.com | Basel, Switzerland | |
| etpventures.com | ||||
R&D company focused on manufacturing drugs for multiple therapeutic areas | 1976 | gene.com | San Francisco, United States |
Investor details for Intradigm Corporation
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Intradigm Corporation
4 dated milestones of Intradigm Corporation across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Intradigm Corporation is founded.
- Funding First funding round of $16.0M.
- Funding Latest funding round, Series B, of $21.4M.
- Exit Acquired by Silence Therapeutics.
Competitors of Intradigm Corporation
Intradigm Corporation has 3 listed competitors in our database, 3 of them funded. They include Denali Therapeutics, C4 Therapeutics and Erasca.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. |
Detailed competitors of Intradigm Corporation
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Intradigm Corporation (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Intradigm Corporation
Complete news archive for Intradigm Corporation
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Intradigm Corporation
Intradigm Corporation was founded in 2000 and raised its 1st funding round 6 years after it was founded.
Intradigm Corporation is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Intradigm Corporation is a funded company, having raised a total of $37.4M across 2 funding rounds to date. The company's 1st funding round was a Series A of $16M, raised on May 2006.
Intradigm Corporation was founded in 2000 and is based in Palo Alto, United States. Focus is placed on the biotechnology sector, where RNA interference therapeutics are developed for serious diseases, starting with oncology. Operations involve the use of proprietary Nanoplex delivery technology, which allows targeted administration to specific tissues via systemic drug delivery methods.
Intradigm Corporation's top competitors include C4 Therapeutics, Erasca and Denali Therapeutics.
Intradigm Corporation has 11 investors. Key investors include Roche, Novartis, Silence Therapeutics, Genentech, and Frazier Healthcare Partners.
Intradigm Corporation operates through Intradigm Corporation.
Yes. Intradigm Corporation was acquired by Silence Therapeutics in December 2009.

